Together, these results suggested that simultaneous treatment with DHA/EPA and bortezomib reduced bortezomib chemosensitivity possibly through activating CDK7-regulated cell cycle progression and inhibiting PTEN and p53 pathways in MM cells. The gene discussed is TP53; the disease is Miyoshi myopathy.